BioCryst Pharmaceuticals Inc (BCRX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at BioCryst Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 9.00 $ — 57% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
7 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 47.8% passed
- More than 10% revenue growth is expected for the coming year 8.5% failed
- Share count grows by less than 3% a year 5.5% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 131.5% passed
- Gross margin at 40% or higher and without meaningful erosion 97.8% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 0.5 x EBITDA passed
- Operating cash flow covers the profits of the last three years 234 m passed
- Return on capital at 15% or higher, or up versus two years ago 107.2% passed
- Insiders hold at least 10% or are net buyers 1.2% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 133.3% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.66 | 0.50 – 0.82 | 669 | 4.0% | 2 |
| 12/31/2027 | 1.00 | 0.75 – 1.25 | 726 | 51.5% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.14 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.13 | – | 132 | 40.80 | -20.40 | -5 | -6 |
| 2025: Q1 | 0.00 | – | 146 | 56.90 | 0.00 | -28 | -28 |
| 2025: Q2 | 0.02 | – | 163 | 49.40 | 3.10 | 41 | 41 |
| 2025: Q3 | 0.06 | – | 159 | 36.10 | 8.10 | 42 | 40 |
| 2025: Q4 | 1.12 | – | 407 | 209.10 | 60.50 | 276 | 275 |
| 2026: Q1 | -2.98 | -2,004,393.60 | 156 | 7.50 | -461.50 | -62 | -63 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 26 | -49 | -55 | -0.75 | -53 | -566 | 90 |
| 2017 | 25 | -57 | -66 | -0.78 | -41 | -632 | 178 |
| 2018 | 21 | -94 | -101 | -0.98 | -93 | -732 | 147 |
| 2019 | 49 | -99 | -109 | -0.94 | -90 | 38 | 175 |
| 2020 | 18 | -175 | -183 | -1.09 | -137 | -19 | 335 |
| 2021 | 157 | -178 | -184 | -1.03 | -142 | -107 | 588 |
| 2022 | 271 | -148 | -247 | -1.33 | -162 | -295 | 550 |
| 2023 | 331 | -104 | -227 | -1.18 | -95 | -456 | 517 |
| 2024 | 451 | -3 | -89 | -0.43 | -52 | -476 | 490 |
| 2025 | 875 | 341 | 264 | 1.21 | 330 | -119 | 514 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
BioCryst Pharmaceuticals, Inc., ein Biotechnologieunternehmen, entwickelt und vermarktet Medikamente für hereditäres Angioödem (HAE) und andere seltene Erkrankungen.
| Employees | 435 |
|---|---|
| Headquarters | Durham, NC |
| Address | 4505 Emperor Boulevard, 27703 Durham, United States |
| Phone | 919 859 1302 |
| Website | biocryst.com |
| IPO Date | 3. Mar 1994 |
| ISIN | US09058V1035 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Charles K. Gayer | CEO, President & Director | 1971 |
| Babar Ghias | CFO & Head of Corporate Development | 1979 |
| Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 1966 |
| John Ruesch | Chief Technical Operations Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.